t-Butyl 4-bromfuran-2-carboxylat | 59862-87-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: t-Butyl 4-bromfuran-2-carboxylat
• 英文别名: 4-bromo-furan-2-carboxylic acid tert-butyl ester；4-bromo-2-furancarboxylic acid tert-butyl ester；Tert-butyl 4-bromofuran-2-carboxylate
• CAS: 59862-87-2
• 化学式: C₉H₁₁BrO₃
• 分子量: 247.089
• InChiKey: QMHKXWRIPNIKSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4,5-二溴呋喃-2-羧酸叔丁酯 在 叔丁基锂 、 盐酸 、 氯化铵 作用下， 以 乙醚 、 正戊烷 、 水 为溶剂， 生成 t-Butyl 4-bromfuran-2-carboxylat
  参考文献：
  名称：

  EP1489077

  摘要：

  公开号：

文献信息

• [EN] PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDINONE ET DE PYRIMIDINONE COMME INHIBITEURS DU FACTEUR XIA
  申请人：ONO PHARMACEUTICAL CO

  公开号：WO2013093484A1

  公开（公告）日：2013-06-27

  The present invention provides compounds of the general formula (I), their salts and N- oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供了一般式(I)的化合物，它们的盐和N-氧化物，以及它们的溶剂合物和前药（其中字符如描述中所定义）。一般式(I)的化合物是因子XIa的抑制剂，因此它们在预防和/或治疗血栓栓塞疾病方面是有用的。
• 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
  申请人：Fujii Akihito

  公开号：US20050171196A1

  公开（公告）日：2005-08-04

  The present invention provides 2-furancarboxylic acid hydrazide compounds represented by General Formula (I) below, and prodrugs, physiologically acceptable salts, hydrates, solvates thereof, methods for producing them and pharmaceutical compositions containing them: wherein A is a group represented by Formula (a) or the like: (wherein either R 4 or R 5 represents cyano, nitro or the like, and the other represents a hydrogen atom or the like); either R 1 or R 2 represents a group: -D-(X)m-R 6 or the like, and the other represents a group: -E-(Y)n-R 7 , hydrogen atom, aryl or the like; R 3 is a hydrogen atom or the like; D and E independently represent aryl; X and Y independently represent O or the like; R 6 and R 7 independently represent alkyl, aryl, arylalkyl or the like; and m and n are independently 0 or 1, provided that the aryl is optionally substituted. Such compounds exhibit a potent antagonistic activity on glucagon receptor and are of use as preventive and/or therapeutic agents for symptoms and diseases in which glucagon is involved.

  本发明提供了由下列通式（I）表示的2-呋喃羧酸肼化合物，以及它们的前药、生理上可接受的盐、水合物、溶剂化物、制备方法和含有它们的制药组合物：其中A是由式（a）或类似式表示的基团：（其中R4或R5代表氰基、硝基或类似物，另一个代表氢原子或类似物）；R1或R2代表基团：-D-(X)m-R6或类似物，另一个代表基团：-E-(Y)n-R7、氢原子、芳基或类似物；R3是氢原子或类似物；D和E独立地表示芳基；X和Y独立地表示O或类似物；R6和R7独立地表示烷基、芳基、芳基烷基或类似物；m和n独立地表示0或1，但芳基可选择性地被取代。这些化合物表现出强大的胰高血糖素受体拮抗活性，并且可用作预防和/或治疗胰高血糖素参与的症状和疾病的药物。
• COMPOUNDS
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20150152112A1

  公开（公告）日：2015-06-04

  The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供了一般式（I）的化合物，它们的盐和N-氧化物，以及它们的溶剂化物和前药（其中字符如描述中所定义）。一般式（I）的化合物是因子XIa的抑制剂，因此它们在预防和/或治疗血栓性疾病方面非常有用。
• 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：DAINIPPON PHARMACEUTICAL CO., LTD.

  公开号：EP1489077A1

  公开（公告）日：2004-12-22

  The present invention provides 2-furancarboxylic acid hydrazide compounds represented by General Formula (I) below, and prodrugs, physiologically acceptable salts, hydrates, solvates thereof, methods for producing them and pharmaceutical compositions containing them: wherein A is a group represented by Formula (a) or the like: (wherein either R4 or R5 represents cyano, nitro or the like, and the other represents a hydrogen atom or the like); either R1 or R2 represents a group: -D-(X)m-R6 or the like, and the other represents a group: -E-(Y)n-R7, hydrogen atom, aryl or the like; R3 is a hydrogen atom or the like; D and E independently represent aryl; X and Y independently represent 0 or the like; R6 and R7 independently represent alkyl, aryl, arylalkyl or the like; and m and n are independently 0 or 1, provided that the aryl is optionally substituted. Such compounds exhibit a potent antagonistic activity on glucagon receptor and are of use as preventive and/or therapeutic agents for symptoms and diseases in which glucagon is involved.

  本发明提供由通式表示的 2-呋喃羧酸酰肼化合物 (I)代表的2-呋喃羧酸酰肼化合物及其原药、生理上可接受的盐、水合物、溶液，以及生产它们的方法和含有它们的药物组合物： 其中 A 是由式（a）代表的基团或类似基团： (其中 R4 或 R5 代表氰基、硝基或类似物，另一个代表氢原子或类似物）； R1 或 R2 代表一个基团：-D-(X)m-R6 或类似基团，另一个代表一个基团：-E-(Y)n-R7、氢原子、芳基或类似基团； R3 是氢原子或类似物； D 和 E 各自代表芳基； X 和 Y 独立地代表 0 或类似物； R6 和 R7 独立地代表烷基、芳基、芳烷基或类似物；以及 m 和 n 独立地为 0 或 1，前提是芳基被任选取代。此类化合物对胰高血糖素受体具有强效的拮抗活性，可用作胰高血糖素相关症状和疾病的预防和/或治疗药物。
• Pyrimidinone and its derivatives inhibiting factor XIa
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US10717738B2

  公开（公告）日：2020-07-21

  The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供通式(I)化合物、其盐类和N-氧化物，以及其溶解物和原药（其中特征如描述中所定义）。通式（I）化合物是因子 XIa 的抑制剂，因此可用于预防和/或治疗血栓栓塞性疾病。